485 related articles for article (PubMed ID: 21392396)
1. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.
Wu X; Subramaniam M; Grygo SB; Sun Z; Negron V; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC; Hawse JR
Breast Cancer Res; 2011 Mar; 13(2):R27. PubMed ID: 21392396
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells.
Secreto FJ; Monroe DG; Dutta S; Ingle JN; Spelsberg TC
J Cell Biochem; 2007 Aug; 101(5):1125-47. PubMed ID: 17520659
[TBL] [Abstract][Full Text] [Related]
3. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
Wu X; Hawse JR; Subramaniam M; Goetz MP; Ingle JN; Spelsberg TC
Cancer Res; 2009 Mar; 69(5):1722-7. PubMed ID: 19244106
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.
Maximov PY; McDaniel RE; Fernandes DJ; Bhatta P; Korostyshevskiy VR; Curpan RF; Jordan VC
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25258390
[TBL] [Abstract][Full Text] [Related]
5. Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens.
Hawse JR; Subramaniam M; Cicek M; Wu X; Gingery A; Grygo SB; Sun Z; Pitel KS; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC
PLoS One; 2013; 8(1):e54613. PubMed ID: 23382923
[TBL] [Abstract][Full Text] [Related]
6. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
[TBL] [Abstract][Full Text] [Related]
7. Nutraceuticals known to promote hair growth do not interfere with the inhibitory action of tamoxifen in MCF7, T47D and BT483 breast cancer cell lines.
Baker R; Dell'Acqua G; Richards A; Thornton MJ
PLoS One; 2024; 19(2):e0297080. PubMed ID: 38408073
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
9. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
Mishra AK; Abrahamsson A; Dabrosin C
Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells.
Monroe DG; Secreto FJ; Subramaniam M; Getz BJ; Khosla S; Spelsberg TC
Mol Endocrinol; 2005 Jun; 19(6):1555-68. PubMed ID: 15802376
[TBL] [Abstract][Full Text] [Related]
11. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
12. ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer.
Reese JM; Suman VJ; Subramaniam M; Wu X; Negron V; Gingery A; Pitel KS; Shah SS; Cunliffe HE; McCullough AE; Pockaj BA; Couch FJ; Olson JE; Reynolds C; Lingle WL; Spelsberg TC; Goetz MP; Ingle JN; Hawse JR
BMC Cancer; 2014 Oct; 14():749. PubMed ID: 25288324
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA
Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444
[TBL] [Abstract][Full Text] [Related]
14. Identification of coregulators influenced by estrogen receptor subtype specific binding of the ER antagonists 4-hydroxytamoxifen and fulvestrant.
Evers NM; Wang S; van den Berg JH; Houtman R; Melchers D; de Haan LH; Ederveen AG; Groten JP; Rietjens IM
Chem Biol Interact; 2014 Sep; 220():222-30. PubMed ID: 25014417
[TBL] [Abstract][Full Text] [Related]
15. Generation of stable reporter breast cancer cell lines for the identification of ER subtype selective ligands.
Shanle EK; Hawse JR; Xu W
Biochem Pharmacol; 2011 Dec; 82(12):1940-9. PubMed ID: 21924251
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens.
Margueron R; Duong V; Bonnet S; Escande A; Vignon F; Balaguer P; Cavaillès V
J Mol Endocrinol; 2004 Apr; 32(2):583-94. PubMed ID: 15072561
[TBL] [Abstract][Full Text] [Related]
17. Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells.
Kallio A; Guo T; Lamminen E; Seppänen J; Kangas L; Väänänen HK; Härkönen P
Mol Cell Endocrinol; 2008 Jul; 289(1-2):38-48. PubMed ID: 18455292
[TBL] [Abstract][Full Text] [Related]
18. Indole-3-carbinol selectively uncouples expression and activity of estrogen receptor subtypes in human breast cancer cells.
Sundar SN; Kerekatte V; Equinozio CN; Doan VB; Bjeldanes LF; Firestone GL
Mol Endocrinol; 2006 Dec; 20(12):3070-82. PubMed ID: 16901971
[TBL] [Abstract][Full Text] [Related]
19. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta.
Tee MK; Rogatsky I; Tzagarakis-Foster C; Cvoro A; An J; Christy RJ; Yamamoto KR; Leitman DC
Mol Biol Cell; 2004 Mar; 15(3):1262-72. PubMed ID: 14699072
[TBL] [Abstract][Full Text] [Related]
20. A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells.
Williams C; Edvardsson K; Lewandowski SA; Ström A; Gustafsson JA
Oncogene; 2008 Feb; 27(7):1019-32. PubMed ID: 17700529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
